Abstract:Stability-indicating analytical methods are developed to monitor the stability of pharmaceutical dosage forms during the investigational phase of drug development, and, once the drug is marketed, for the ongoing stability studies which must be conducted. The development of these methods for pharmaceutical dosage forms forms can be approached from several avenues. Methods can be developed which measure the amount of drug remaining, the amount of drug lost (or the appearance of degradation products), or both. Traditionally, the analytical methods used to monitor the stability of dosage forms have involved a generally non-specific spectrophotometric or titrimetric procedure for the assay of the active coupled with thin layer chromatography for the estimation of impurities and degradation products. In the last five years, this approach has changed dramatically. Currently, the method of choice for the quantitation of the active and degradation products is rapidly becoming high performance liquid chromatography. This method has obvious advantages since it both separates and measures and it lends itself well to automation. The disadvantages are that, in the absence of automation, the technique can be time-consuming, it is by no means universal, and it is relatively expensive. Recent advances in column technology have reduced some separation times to seconds and, in the next few years, this technique may find even greater utility. HPLC, however, is not the only way to go. Other chromatographic methods still find a place, particularly gas chromatography when the stability of the component of interest does not pose a problem and thin layer chromatography for the rapid determination of degradation products. Other methods may also be used, including electrometric, e.g., polarography, and spectrophotometric, e.g., fluorimetry or NMR. The choice of an appropriate method must depend on both a scientific and practical evaluation of the drug and its dosage form. Once an analytical method is chosen, the most important aspect of the development of a stability-indicating procedure is method validation. Validation should include evaluation of the following parameters: specificity, linearity, precision, accuracy, sensitivity, and ruggedness. There are many other aspects to stability that could also be considered, e.g., the stability of the bulk drug and physical and organoleptic changes in a dosage form. These should be part of a separate discussion. It very often happens that, during the course of product development, analytical methods evolve. As more is learned about the drug and its dosage form, methods can be refined and revised.

Estimating Shelf Life Through Tolerance Intervals Extended to Nonlinear Response Trends

A Modern Approach to Stability Studies via Bayesian Linear Mixed Models Incorporating Auxiliary Effects

Stability Modeling Methodologies to Enable Earlier Patient Access

Shelf-life and its estimation in drug stability studies

An Approach to Drug Stability Studies and Shelf-life Determination

Statistical considerations for design and analysis of stability, comparability and formulation tests

Matrixing Designs for Shelf-Life Determination of Parenteral Drug Product: A Comparative Analysis of Full and Reduced Stability Testing Design

Accelerated Stability Testing in Food Supplements Underestimates Shelf Life Prediction of Resveratrol with Super-Arrhenius Behavior

Assessing Drug Product Shelf Life Using the Accelerated Stability Assessment Program: A Case Study of a GLPG4399 Capsule Formulation

Development, Comparison, and Qualification of Predictive Pharmaceutical Stability Models Using Independent Statistical Tools

Bayesian hierarchical modeling of drug stability data

Prediction of the physical stability of amorphous solid dispersions: relationship of aging and phase separation with the thermodynamic and kinetic models along with characterization techniques

Early clinical drug product shelf-life setting using accelerated predictive stability and metabolite data for impurity qualification: A case study

Drug Stability: ICH versus Accelerated Predictive Stability Studies

Multivariate Mixed-Effects Kinetic Models for Multiple Correlated Quality Attributes from Accelerated Stability Studies

An Inventory Model for Deteriorating Drugs with Stochastic Lead Time

Assay Development in Stability Test Methods

A Unified Framework for Detecting Out-of-Trend Results in Stability Studies

Development of a predictive algorithm for the efficacy of half-life extension strategies

Temperature Excursion Management: A Tier-Based Approach for Commercial Oral Solid Dosage Forms

Optimal Stress Levels in Accelerated Degradation Testing for Various Degradation Models